Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Breakthrough Company????? Endovasc ENDV -- Ignore unavailable to you. Want to Upgrade?

To: Jacalyn Deaner who wrote (21)	4/10/1999 6:41:00 PM
From: NY_Know	Respond to of 94

The Need According to the American Heart Association, in 1996, over 60 million Americans had one or more types of cardiovascular disease. In 1993, the latest data available, over 950,000 cardiovascular disease deaths occurred, making it the number one cause of death in the U.S. and 42% of all deaths. By comparison, the estimated 1993 total of U.S. cancer deaths was 530,000. Not surprisingly, cardiovascular disease impacts the U.S. health care system tremendously and, as the population ages, it will almost assuredly continue to burden health care resources. Despite increases in cardiovascular disease incidences, advances in medical technology and scientific knowledge in the past 30 years are witness to dramatic death rate declines (over 50% in the U.S.) from cardiovascular disease. Angioplasty, an intravascular balloon catheter that clears blocked arteries and places stents, has only been used for 20 years. According to the American Heart Association, half of all blood vessel blockages receive angioplasty treatment, with the remainder undergoing bypass or medical therapy. Even though fewer bypasses are performed, restenosis, the re-blocking of a previously cleared artery, commonly occurs with angioplasty. In 1993, some 600,000 angioplasty procedures were performed worldwide (U.S. Insurance Claims Database) with over 40% of the patients developing restenosis within three to six months. Repeat angioplasty causes more than 2,500 deaths and costs approximately $3.5 billion. Opportunities abound for companies that can develop cost-effective cardiovascular disease treatments while reducing trauma and improving patient outcome. Endovasc's management believes its goal of $100 million in revenue can be reached within three years of FDA approval of its cost-effective PGE-1 stent coating and related products. Management views the Cook Endovascular research agreement as major step in validating PGE-1 as an effective restenosis reduction method. Endovasc anticipates strong subsequent demand for PGE-1 upon its approval.

To: Jacalyn Deaner who wrote (21)	4/10/1999 6:42:00 PM
From: NY_Know	Respond to of 94

The Product Prostaglandin E1 PGE-1 Endovasc's main product, lyophilized liposomal Prostaglandin E1 (PGE-1), is a site-specific drug delivery method for treating vascular restenosis and thrombosis (vascular blood clot) through intravascular balloons during angioplasty and stent use. PGE-1 is a potent, naturally occurring hormone that shows encouraging indications of preventing second blockage, or restinosis, if used concurrently with angioplasty. Unfortunately, PGE-1 survives in the blood stream for less than one minute. To combat the short lifecycle, Endovasc recently developed a Prostaglandin delivery method that places Prostaglandin into microscopic-size particles. The particles constitute an "artificial cell" called a liposome, which can penetrate the diseased vessel wall. Upon penetration, the liposome is designed for timed release within the vessel wall, providing controlled drug release over a matter of days as opposed to minutes. Recent studies at the Baylor College of Medicine and the Texas Heart Institute of Houston demonstrated a reduction in restenosis in a pig model. This study not only showed inhibited smooth muscle cell proliferation, but stabilization of vessel wall remodeling. Preliminary research indicates that this perplexing reoccurring disease may be prevented, opening a very large market for PGE-1 in treating forms of cardiovascular disease. Further results will be released after the concurrent studies of PGE-1 at the Polyclinique d' Essey-les-Nancy and University of Texas at Houston, focusing on limb salvage for patients faced with amputation, have begun. The method of using small drug-carrying liposomes is on the forefront of a new era in drug treatment, x-ray imaging and MRI imaging.

To: Jacalyn Deaner who wrote (21)	4/10/1999 6:43:00 PM
From: NY_Know	Respond to of 94

Management David P. Summers, Ph.D., MBA, FACA, is the CEO and Chairman of the Board. Dr. Summers is a Fellow of the American College of Angiology and has over 30-year's work in medicine, including medical device and drug delivery development. He is inventor of several liposomal drug delivery systems and medical devices and is author of 20 patents and has eight patents pending. Dr. Summers founded American BioMed, Inc. (NASDAQ: ABMI) in 1984 and served as its President and CEO until 1995. Danilo D. Lasic, Ph.D., Chief Scientific Officer, is an internationally known physical scientist specializing in liposomal and nanoparticle drug delivery. Formerly with Liposomal Technology, Inc. (now Sequus), he served as Senior Scientist where he led studies for theoretical understanding of long-circulating liposomes. Considered as one of the principal developers of the "Stealth Liposome," he was primarily active in the scale-up of the liposome-laden anti-cancer drug, doxorubicin. Dr. Lasic has published over 150 papers, co-authored a four-book series and authored a monograph, Liposomes: From Physics to Application (Elservier, 1993). Gary R. Ball, B.A. is COO, VP of R&D, Treasurer and Director. Mr. Ball is degreed in Electrical and Mechanical Engineering with extensive experience in microprocessor technology and R&D. He is co-inventor of three U.S. patents and has 10-years experience in manufacturing, regulatory and clinical trials. M. Dwight Cantrell, Controller, CFO and Director., is degreed in accounting and has 30 years experience in public accounting and as CFO of a major electrical contractor. Since 1987, he has served as a consultant to large Southwestern banks brokering or facilitating transactions of up to $100 million. John G. Charles, Exec. VP and Director, is a medical technologist who develops early-stage companies specializing in marketing and exporting medical instrumentation and diagnostic products to laboratories. He spent 25 years in microscope, microtome and clinical chemistry systems sales management for American Optical and Warner Lambert.

To: Jacalyn Deaner who wrote (21)	4/11/1999 3:50:00 PM
From: Dr David Summers	Read Replies (2) \| Respond to of 94

Thank you for the update, Jackie Our Chief Scientist, Dr. Dan Lasic (his disiplain is solid-state physics) is also consulting with Roche in Palo Alto. If your husband has any engineering question regarding the design and development of our liposome drug delivery systerm, you can e-mail him ain care of: endovasc.lcc.net, and I will forward the qyery to him. Bye- the-way, the weather here in Houston is beautiful as well...besides the perennial Blue Bonnets, we have a blaze of Indian Blanket,pink Butter Cups, yellow Daisies, Black-eyed Susans, and a smathering of Echinasia. Enjoy...its the best tiime of the year!